Sialorrhea (Excessive Drooling) Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Safety and Efficacy of Tropicamide 1 mg Intra-oral Slow Dissolving Muco-adhesive Thin Films to Reduce Hypersalivation in PD Patients Manifesting Sialorrhea Complaints
To study the safety and efficacy of tropicamide 1 mg intra-oral slow dissolving muco-adhesive thin films compared to placebo to reduce hypersalivation in PD patients manifesting sialorrhea complaints.
| Status | Completed |
| Enrollment | 30 |
| Est. completion date | December 2015 |
| Est. primary completion date | October 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 30 Years and older |
| Eligibility |
Inclusion criteria: - Patients with idiopathic Parkinson's disease, according to the UK Brain Bank criteria. - Patients complaining of drooling, with a score of at least 6 points in the SCS-PD scale. - Patients above 30 years old. - Patients with Hoehn & Yahr score between I-IV. - Male or non-pregnant female. Females of child-bearing potential will be required to have undergone a pregnancy test with negative results prior to entry to the study and agree to use contraceptive measures for the duration of the study. - Patients must have used the same antiparkinsonian medications and at the same dose for the last month. No changes in the medication for PD are expected during the study. Exclusion criteria: - Pregnant women. - Patients with a secondary parkinsonian syndrome, parkinsonism-plus syndromes, heredodegenerative disorders or benign parkinsonism. - Patients with a diagnosis of major depression or psychosis according to the DSM-IV. - Patients with MMSE score equal to or lower than 24. - Patients with a current diagnosis of substance abuse (DSM-IV) or history of alcohol or drug abuse in the past 3 months. - Patients with hallucinations. - Patients with a current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including hypertension that is not well-controlled, asthma, chronic obstructive pulmonary disease (COPD) and Type I diabetes. - Patients with a second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or significant ECG abnormality, including QTc = 450 msec (males) or = 470 msec (females), where QTc is based on Bazett's correction method. - Patient with a neoplastic disorder, which is either currently active or has been in remission for less than one year. - Patients with a history or a current diagnosis of HIV, or tests positive for Hepatitis B or C antibodies, or Hepatitis B surface antigen - Patients who have participated in a previous clinical trial within 30 days of entry into the study (screening visit) or have received treatment with any investigational compound within 30 days. - Patients with hypersensitivity to atropine or other anticholinergic drugs. - Patients who have experienced adverse effects as a result of taking anticholinergic drugs. - Patients who are receiving any anticholinergic drug or an anticholinesterase agent. - Patients who started or changed the dose of any of the following medications in the previous week: tricyclic antidepressants, monoamine oxidase-A inhibitors, antipsychotics, benzodiazepines, opioids, antihistamines, carbamazepine, NSAIDs. - Patients with significant dental/oral pathology. - Patient with any abnormality that the investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in a diagnostic laboratory test. - Patients with closed-angle Glaucoma or those at high risk of suffering it after treatment with anticholinergic agents. - Patients with Prostatic Adenoma. - In the judgment of the Clinical Investigator, the patient is likely to be non-compliant or uncooperative during the study. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital Haut Lévêque | Bordeaux | Pessac |
| France | Hôpital de la Salpêtrière | Paris | Cedrex 13 |
| France | Hôpital Paul de Viguier | Toulouse | Cedrex 9 |
| Lead Sponsor | Collaborator |
|---|---|
| NeuroHealing Pharmaceuticals Inc. | Michael J. Fox Foundation for Parkinson's Research |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | modified Teachers Drooling Scale (% responding) | The primary endpoint for this trial is the difference in responder rate between tropicamide and placebo. Responders will be defined as subjects whose mean sialorrhea score improved by at least 30% as compared to baseline in the 9-point modified Teachers Drooling Scale (mTDS). | one week | No |
| Secondary | modified Teachers Drooling Scale (mean) | Difference in the mean sialorrhea scores between placebo and tropicamide in the 9-point modified Teachers Drooling Scale (mTDS). | one week | No |
| Secondary | Sialorrhea Clinical Scale for Parkinson's Disease (mean) | - Difference in the mean sialorrhea scores between placebo and tropicamide in the Sialorrhea Clinical Scale for Parkinson's Disease (SCS-PD). | one week | No |
| Secondary | UPDRS Part II sialorrhea item (mean) | Difference in the mean sialorrhea scores between placebo and tropicamide in the UPDRS Part II sialorrhea item (#6). | one week | No |
| Secondary | Visual Analg Scale | Saliva buccal content as measured by a Visual Analog Scale (VAS) score, evaluated before and during 3 hours after treatments administration. | one week | No |